Patients who received Johnson & Johnson's Cypher drug-coated stent were less likely to suffer heart attacks than patients who received Boston Scientific Corp.'s Taxus stent and bare-metal stents, a study revealed. Researchers also found that Taxus stents slightly increased the risk of fatal clots in patients compared with Cypher and bare-metal stents.

Full Story:

Related Summaries